A Phase III, Randomized, Controlled and Multi-center Study of AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

560

Participants

Timeline

Start Date

May 9, 2025

Primary Completion Date

January 13, 2027

Study Completion Date

January 7, 2029

Conditions

Colorectal Adenocarcinoma

Interventions

DRUG

AK112

iv, q2w

DRUG

Oxaliplatin

iv, q2w

DRUG

Irinotecan

iv, q2w

DRUG

Leucovorin and 5-FU

iv, q2w

DRUG

Bevacizumab

iv, q2w

Trial Locations (2)

The Sixth Hospital,Sun Yat-sen University, Guanzhou

Sun Yat-sen University Cancer Center, Guanzhou